We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

14 hedge funds and large institutions have $2.78M invested in VistaGen Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,501% more capital inflows, than outflows

Capital inflows: $950K | Capital outflows: $59.4K

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

5.48% more ownership

Funds ownership: 13.26% → 18.74% (+5.5%)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Sphera Funds Management
Sphera Funds Management
Israel
+$903K
2
Citadel Advisors
Citadel Advisors
Florida
+$23.5K
3
Bartlett & Co
Bartlett & Co
Ohio
+$17.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$6.53K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$48K
2
UBS Group
UBS Group
Switzerland
-$10.4K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1K

VTGN Hedge Fund Activity: Q3 2017 in Review

14 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2017, worth a combined $2.78M — up 21% from $2.3M a quarter earlier.

Fund positioning in VTGN was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $903K. The largest seller was Sabby Management, exiting entirely with an estimated $48K sold.

  • 14 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $2.78M of VistaGen Therapeutics stock for Q3 2017, up 21% quarter-over-quarter.
  • 2 funds opened new VistaGen Therapeutics positions in Q3 2017 and 2 closed out, a net change of 0 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2017 was Sphera Funds Management, an estimated $903K added.
  • The largest VistaGen Therapeutics seller in Q3 2017 was Sabby Management, an estimated $48K sold.

Based on aggregated 13F filings for Q3 2017.